COMPOZITII FARMACEUTICE PENTRU ACTIVITATEA SEMNALIZARII RECEPTORULUI LIMFOTOXINA- BETA

Price not visible for this package

Interest:

Assignment

Publication info:

No.: RO118634

Date: 29.08.2003

Inventor(s):

BROWNING JEFFREY L [US]

MEIER WERNER [US]

BENJAMIN CHRISTOPHER D [US]

Applicant(s):
BIOGEN INC [US]
Classification:
International patent classification (IPC):
A61K38/00; A61K38/19; A61K38/21; A61K39/395; A61P35/00; C07K14/525; C07K14/715; C07K16/28; C12N5/20; C12P21/08; G01N33/566; G01N33/00

Cooperative patent classification (CPC):
A61K38/19 (KR); A61K38/191 (EP); A61K39/395 (EP, KR); A61K39/39541 (EP); A61P35/00 (EP); C07K14/525 (EP); C07K14/715 (EP); C07K16/2866 (EP); A61K2039/505 (EP); C07K2317/73 (EP); C07K2317/74 (EP); C07K2319/00 (EP); C07K2319/30 (EP); A61K38/191; A61K2300/00; A61K39/395; A61K39/39541
Application info:
No.: RO19970001398
Date: 26.01.1996
Priority number(s):
US19950378968 26.01.1995 ; WO1996US01386 26.01.1996
Related patents:
ATE268604; AU4970496; AU725351; BG101855; BG62599; BR9606808; CA2211443; CN1146442; CN1177302; CN1589902; CN1900116; CZ236197; CZ298711; DE69632681; DK0809510; EA000096; EA199700144; EE04453; EE9700255; EP0809510; EP1407781; ES2220972; FI119359; FI973118; HK1006356; HU9801746; JP2007169296; JPH10513161; KR100470739; KR100475492; KR19980701816; KR20040102364; MX9705629; NO322744; NO973385; NZ303405; PL185364; PL321758; PT809510; SK286497; SK98697; WO9622788
Description:

Inventia se refera la compozitii pentru activarea semnalizarii receptorului limfotoxina-beta, care in schimb provoaca efecte antiproliferative potentiale asupra celulelor tumorale. Aceasta inventie se refera de asemenea, la complexe heteromerice limfotoxina formate intre limfotoxina-alfa si subunitati multiple ale limfotoxinei-beta, care induc efecte citotoxice asupra celulelor tumorale, in prezenta agentilor care activeaza receptorul limfotoxina-beta. Inventia prezinta anticorpi indreptati impotriva receptorului limfotoxina-beta, care actioneaza ca agenti de activare receptori limfotoxina-beta, singuri sau in combinatie cu alti agenti de activare receptor limfotoxina-beta, in prezenta sau absenta complexelor limfotoxina-alfa/beta.